Literature DB >> 24619955

Past and current hepatitis E virus infection in renal transplant patients.

Tiago Hering1, Ana Maria Passos, Renata Mello Perez, Juliana Bilar, Daniel Fragano, Celso Granato, José Osmar Medina-Pestana, Maria Lucia Gomes Ferraz.   

Abstract

The chronic course of hepatitis E virus infection in immunosuppressed patients has been recently documented; however, clinical features and factors associated with this occurrence are not well known. The aim of this study was to evaluate the prevalence of previous or current HEV infection in renal transplant patients. One hundred ninety-two kidney transplant patients were studied and classified in three groups: G1-infected with hepatitis B and/or C virus; G2-patients with elevated ALT; G3-patients with normal ALT and no hepatotropic virus infection. Demographic, epidemiologic and clinical characteristics were compared between the groups. Patients with HEV infection (previous or current) were also compared to those who tested negative for HEV. HEV infection was detected using serologic (anti-HEV IgG) and molecular (HEV RNA) methods. Anti-HEV IgG was positive in 28 (15%) while HEV RNA was positive in 20 (10%). When both markers were considered, 44 (23%) patients showed evidence of previous or current HEV infection. However, both markers were concomitantly positive in only four cases (2%). In the comparative analysis, patients infected with HBV and/or HCV showed lower frequency of anti-HEV IgG (P = 0.009). There was no difference regarding demographic, epidemiologic and laboratory variable between viremic and non-viremic patients. In conclusion, past and current infection with HEV was a frequent finding among renal transplant recipients. Actively infected patients (HEV RNA positive) did not present distinct demographic and epidemiological characteristics or laboratory alterations suggestive of underlying liver damage. Therefore, infection with HEV can only be detected in immunosuppressed patients by systematic investigation of HEV RNA.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALT; HEV RNA; anti-HEV; hepatitis E; kidney transplantation

Mesh:

Substances:

Year:  2014        PMID: 24619955     DOI: 10.1002/jmv.23915

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Lack of persistent hepatitis E virus infection as a cause for unexplained transaminase elevation in renal transplant recipients in India.

Authors:  Sachin Munjal; Neha Gupta; Raj K Sharma; Amit Gupta; Narain Prasad; Anupama Kaul; Dharmendra Bhadauria; Amit Goel; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2014-10-01

2.  Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis.

Authors:  Nathalie Verónica Fernández Villalobos; Barbora Kessel; Isti Rodiah; Jördis Jennifer Ott; Berit Lange; Gérard Krause
Journal:  PLoS One       Date:  2022-06-01       Impact factor: 3.752

Review 3.  Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients.

Authors:  Karthik Kovvuru; Nicholas Carbajal; Abhinandan Reddy Pakanati; Charat Thongprayoon; Panupong Hansrivijit; Boonphiphop Boonpheng; Pattharawin Pattharanitima; Voravech Nissaisorakarn; Wisit Cheungpasitporn; Swetha R Kanduri
Journal:  World J Hepatol       Date:  2022-03-27

4.  Hepatitis e infection in a renal transplant recipient.

Authors:  Diana Vassallo; Mir Mubariz Husain; Shaun Greer; Stephen McGrath; Samreen Ijaz; Durga Kanigicherla
Journal:  Case Rep Nephrol       Date:  2014-09-11

5.  High frequency of hepatitis E virus infection in swine from South Brazil and close similarity to human HEV isolates.

Authors:  Ana Maria Passos-Castilho; Celso Francisco Hernandes Granato
Journal:  Braz J Microbiol       Date:  2017-01-03       Impact factor: 2.476

6.  Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.

Authors:  Noemi Rovaris Gardinali; Juliana Rodrigues Guimarães; Juliana Gil Melgaço; Yohan Britto Kevorkian; Fernanda de Oliveira Bottino; Yasmine Rangel Vieira; Aline Campos de Azevedo da Silva; Douglas Pereira Pinto; Laís Bastos da Fonseca; Leandro Schiavo Vilhena; Edilson Uiechi; Maria Cristina Carlan da Silva; Julio Moran; Renato Sérgio Marchevsky; Oswaldo Gonçalves Cruz; Rodrigo Alejandro Arellano Otonel; Amauri Alcindo Alfieri; Jaqueline Mendes de Oliveira; Ana Maria Coimbra Gaspar; Marcelo Alves Pinto
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

7.  A mutation in the progesterone receptor predisposes to HEV infection in HIV-positive patients.

Authors:  Jose D Debes; Suzan D Pas; Zwier M A Groothuismink; Marchina E van der Ende; Robert A de Man; Andre Boonstra
Journal:  Liver Int       Date:  2018-01-19       Impact factor: 5.828

8.  Seroprevalence of hepatitis E virus in risk populations and blood donors in a referral hospital in the south of Brazil.

Authors:  Marisa Boff Costa; Michele Soares Gomes Gouvêa; Samira Chuffi; Gustavo Hirata Dellavia; Felipe Ornel; Lísia Von Diemen; Félix Kessler; João Renato Rebello Pinho; Mário Reis Álvares-da-Silva
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

9.  Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil.

Authors:  Raquel Silva do Nascimento; Karen Lorena N Baia; Samara Borges de Souza; Guilherme Martins G Fontoura; Patrícia Ferreira Nunes; Luiz Fernando A Machado; Emil Kupek; Benedikt Fischer; Luísa Caricio Martins; Aldemir B Oliveira-Filho
Journal:  Viruses       Date:  2021-05-17       Impact factor: 5.048

10.  Increased Hepatitis E Virus Seroprevalence Correlates with Lower CD4+ Cell Counts in HIV-Infected Persons in Argentina.

Authors:  José D Debes; Maribel Martínez Wassaf; María Belén Pisano; María Beatriz Isa; Martin Lotto; Leonardo G Marianelli; Natalia Frassone; Estefania Ballari; Paul R Bohjanen; Bettina E Hansen; Viviana Ré
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.